linjc16/ctgov huggingface dataset:
Characteristics of Tuberculosis Infection in Rheumatic Disease

Study Overview
=================
Brief Summary
-----------------
A retrospective study evaluating the characteristics of tuberculosis infection in patients of rheumatic disease.

Official Title
-----------------
Retrospective Analysis of Tuberculosis in Rheumatic Diseases for Epidemiology, Risk Factors, Disease Presentation, Complications, Treatment, and Prognosis

Conditions
-----------------
Tuberculosis, Autoimmune Diseases

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patients with International Classification of Diseases (ICD) codes of rheumatic diseases during 2006-2017 Definite evidence of tuberculosis infection Exclusion Criteria: HIV, malignancy, not follow-up rheumatic disease in National Taiwan University Hospital, younger than 20-year-old, refusing attend research

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention|We group the patients according to the outcome (survival vs mortality)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | Death of any cause (The definition of TB mortality from WHO is death of any cause during TB treatment.) | approximately 6 months |
Tolerance of a Calorically Dense Enteral Nutrition Formula

Study Overview
=================
Brief Summary
-----------------
This prospective observational study seeks to demonstrate the ability to meet nutritional needs of a calorically dense enteral formula in critically ill patients.

Official Title
-----------------
Tolerance of a Calorically Dense Enteral Nutrition Formula

Conditions
-----------------
Enteral Feeding

Intervention / Treatment
-----------------
* Other: Enteral Formula


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult aged > 18 years Admitted to Medical ICU with expected admission of ≥ 3 days Established enteral access Having obtained his/her or legal representative's informed consent. Exclusion Criteria: Pregnant or lactating Condition which contraindicates enteral feeding (i.e. intestinal obstruction) Lack of enteral access Parenteral nutrition Any condition that would contraindicate use of the study product (i.e. need for severe fluid restriction, cow's milk protein allergy, etc.) Subject who in the Investigator's assessment cannot be expected to comply with study protocol Currently participating in another conflicting clinical trial.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| enterally fed adults<br>Adults subjects with a condition for which a calorically dense enteral formula is appropriate, with established enteral access, anticipated to require enteral tube feeding for at least 3 days. | Other: Enteral Formula<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Daily percentage of caloric nutritional goal met |  | First 3 days in the ICU | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Daily percentage of protein goal met |  | First 5 days in the ICU | 
| Adverse events and serious adverse events |  | First 5 days in the ICU |
Drug Delivery and Toxicities of Adjuvant Chemotherapy in Resected NCSLC

Study Overview
=================
Brief Summary
-----------------
There are limited numbers of retrospective studies showing the effectiveness of adjuvant chemotherapy over observation in resected lung cancers.

Detailed Description
-----------------
We propose to retrospectively examine the Washington University School of Medicine experience on all patients receiving adjuvant chemotherapy between 2003 and 2005. We will retrospectively analyze the survival and outcomes in the lung cancer patients receiving adjuvant chemotherapy following surgical resection.

Official Title
-----------------
Drug Delivery and Toxicities of Adjuvant Chemotherapy in Resected Non Small Cell Lung Cancer

Conditions
-----------------
Adjuvant, Chemotherapy, Lung, Cancers

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients that received adjuvant chemotherapy 18-88 years Exclusion Criteria: Any patients that have not received adjuvant chemotherapy Patients under 18 or over 88

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 88 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
adjuvant, chemotherapy, observation, resected, cancers
Genetic Variants Modulate Association Between Dietary n-3 LCPUFAs and DHA Proportion in Breast Milk

Study Overview
=================
Brief Summary
-----------------
DHA is important for the development of brain and retina in newborns. Considering that exclusive breast feeding for at least 4  6 months are globally recommended, plus it is well known that nutrient requirement is determined by both genetic and environmental (including diet) factors, this clinical study sought to investigate how the DHA levels in maternal milk is modulated by genetic variants and dietary n-3 LCPUFA intake. To recruit subjects (n=193), the inclusion criteria are Han Chinese women just having delivered full-term baby, 20-40 years old, healthy, and willing to breast feed their baby for at least 2 months. Written informed consent will be obtained from participants. Personal information (or covariates) such as height, weight (before getting pregnancy and delivery, respectively), age, parity, education, smoking, alcohol drinking, gender of baby…etc, and DNA from oral swab will be collected. Breast milk and dietary data will be collected at the end of the 1st and 2nd month of postpartum period. Considering Han Chinese women usually have special postpartum diets and care during puerperium, therefore, collection of breast milk and dietary information will be repeated at the 2nd month. The fatty acid composition in milk will be analyzed by gas chromatography. Using food frequency questionnaire, intake of n-3 LCPUFA from foods + fish oil supplements will be calculated. Subjects will be instructed to give a 3-days food record as well. We foresee results of this study might contribute to public health care as nutritionists/dietitians will be able to target the vulnerable subjects, who are dietary dependent for DHA, for dedications in nutrition consults or customized dietary guidance. Moreover, these information are valuable in making policy regarding dietary recommendation in Taiwan.

Official Title
-----------------
Genetic Variants Modulate Association Between Dietary n-3 LCPUFAs and DHA Proportion in Breast Milk

Conditions
-----------------
Fatty Acid Desaturases, Polymorphism, Single Nucleotide, Milk, Human

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Han Chinese women Full-term pregnancy(>36weeks) 20-40 years old Healthy Breast feed their baby for at least 2 months Exclusion Criteria: Death before and after childbirth Child with congenital disease

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Breast milk fatty acid composition | Breast milk will be collected at the end of the 1st and 2nd month of postpartum period.The fatty acid composition in milk will be analyzed by gas chromatography. | 2 month |
Neuropsychoanalytic Treatment of Failed Back Surgery Syndrome-Opioid Dependence

Study Overview
=================
Brief Summary
-----------------
Opioid Dependent Patients who have failed back surgery syndrome are detoxified and treated with a neuropsychoanalytic paradigm.

Detailed Description
-----------------
Patients were detoxified from opioid analgesics and treated with NSAIDs and other non-opioid analgesics, received neuropsychoanalytic therapy and low dose naltrexone. Patients kept a daily diary of: 0 - 10 pain, 0 - 10 function, hours worked, amount of alcohol drunk, illicit and licit drug use, number of health care provider appointments attended, number of self-help groups meetings attended across each of the six months of study. Six month outcomes of this approach with primary outcomes being sobriety, pain scores and function scores.

Official Title
-----------------
Neuropsychoanalytic Treatment of Failed Back Surgery Syndrome-Opioid Dependence

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Behavioral: Neuropsychoanalytic therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have failed back surgery syndrome. Have evidence of Opioid Dependence by meeting DSM-IV criteria and by Drug Abuse Screening Test > 4. (In case of a difference in these two measures, clinical staff will talk with the patient to adjudicate the difference.) Over 18 Be able to understand spoken and written English Reside within 30 miles of the site of treatment for ease of followup Have health insurance or other ability to pay for treatment Exclusion Criteria: Homeless Unable to give consent (e.g. neurological disorders, dementia, psychosis) Co-occurring incapacitating psychiatric disorder such as schizophrenia Pregnant Financial incentive to stay ill, such as a pending disability claim Member of a vulnerable population, including prisoners

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Neuropsychoanalytic treatment<br>Outpatient detoxification, intensive neuropsychoanalytic therapy, low dose naltrexone, monthly evaluations for six months - case series approach. | Behavioral: Neuropsychoanalytic therapy<br>* Psychotherapy, medication management<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement of pain | Detoxified patients followed for whether their pain improved. | Six months |
Automated Connective Tissue Torque Sensor

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to develop a measure - the needle torque test - capable of detecting connective tissue abnormalities associated with musculoskeletal disorders.

Detailed Description
-----------------
Chronic musculoskeletal pain is a source of considerable disability, work absenteeism and health care costs. A major obstacle to the treatment of these conditions is the lack of methods to objectively assess connective tissues and measure the effect of treatments. Needle torque test technology under development in this project will potentially enable objective measurement of connective tissue abnormalities associated with musculoskeletal pain and dysfunction. This could help evaluate the efficacy of various treatments and enhance the objective monitoring of patient progress in clinical practice.

Official Title
-----------------
Automated Connective Tissue Torque Sensor

Conditions
-----------------
Connective Tissue, Musculoskeletal Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria for chronic low back pain subjects: back pain that has disrupted activity for more than half the days in the past 12 months. Inclusion Criteria for restricted hamstring subjects: 90/90 test of more than 20 degrees Inclusion Criteria for systemic scleroderma subjects: physician diagnosis Inclusion criteria for joint hyperlaxity subjects: Beighton test score of 7 or higher Exclusion Criteria for all subjects: surgery or scars in thighs or low back neurological or major psychiatric disorder bleeding disorders acute systemic infection pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy controls<br> | |
| Chronic low back pain<br> | |
| restricted hamstrings<br> | |
| systemic scleroderma<br> | |
| joint hyperlaxity<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of needle revolutions to achieve threshold torque |  | Time zero, 30 minutes and one week |
Tumor Lysate Pulsed-Dendritic Cell Vaccines After High-Dose Chemotherapy for Non-Hodgkin's Lymphoma

Study Overview
=================
Brief Summary
-----------------
When patients relapse after primary chemotherapy for Non-Hodgkin's lymphoma, they may be eligible to receive high-dose chemotherapy with autologous stem cell support. Unfortunately high-dose chemotherapy is curative in less than half the patients who receive it. This study is being conducted to determine the safety, side effects, and the ability to respond to an investigational vaccine that consists of tumor-pulsed dendritic cells given with an immune stimulating drug called interleukin-2. The patient must have a lymphomatous node accessible for excision to prepare the vaccine. Dendritic cells are immune cells that are obtained from the blood, and are important in the body's immune response to foreign substances. This study will examine the response of the immune system after three vaccinations (composed of dendritic cells, which have been exposed to dead fragments of lymphoma cells) given beginning three months after transplant. Vaccination may result in sensitizing the patient's dendritic cells to his lymphoma cells, potentially resulting in an immune response against the lymphoma. Twelve patients will be treated on study.

Conditions
-----------------
Lymphoma, Non-Hodgkin

Intervention / Treatment
-----------------
* Biological: tumor-pulsed dendritic cells


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically documented, aggressive and/or intermediate grade NHL, B-cell and T-cell. In relapse after first-line conventional chemotherapy. Primary therapy should include a doxorubicin-based regimen. Patients must have disease sensitive to induction chemotherapy, radiation therapy, and/or radioimmunotherapy. Successful treatment of CNS or meningeal disease is allowed. Patients must have accessible tumor for biopsy or excision. Cumulative total doxorubicin: <500 mg/m2 Performance score 0-2 No prior pelvic RT Patients with a prior malignancy are eligible if they were treated for cure and have no evidence of active disease. Patients may not be taking immunosuppressive agents. Informed Consent; IRB approval

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: tumor-pulsed dendritic cells|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dendritic cells
Gastric Tube in Pyloric Stenosis

Study Overview
=================
Brief Summary
-----------------
Pyloric stenosis is a current condition in pediatric surgery. The medical management prior to surgery consists of ionic correction. The nasogastric tube is commonly used to prevent gastric fluid inhalation before surgery, but there is no study on it benefits in this specific use. Other studies suggest that utilization of a gastric tube in pyloric stenosis may increase the duration of the medical treatment. The aim of the study is to evaluate the benefit of the nasogastric tube to prevent respiratory complications. This retrospective, monocentric and descriptive study include all patients hospitalized for pyloric stenosis in the university hospital in Amiens between 2014 and 2021. Patients with and without nasogastric tube prior to surgery are compared, regarding respiratory complications define as use of antibiotic, or oxygen therapy or infection in the lungs X-ray before surgery. The investigators analyze pre-operative data: vomiting, dehydration, time to ionic disorders correction and pain, and also notice the length of hospital stay. Data during hospitalization are analyzed and will be noticed the last medical contact represent by the post-operative consultation.

Official Title
-----------------
Role of the Gastric Tube in the Preoperative Management of Hypertrophic Pyloric Stenosis

Conditions
-----------------
Hypertrophic Pyloric Stenosis, Respiratory Complication

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients with hypertrophic pyloric stenosis Exclusion Criteria: refusal of data collection and use from patient's parent or family

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 1 Year

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with nasogastric tube before surgery<br> | |
| patients without nasogastric tube before surgery<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| occurrence of respiratory complications before surgery | respiratory complications are defined by antibiotic use and/or oxygenotherapy and/or infection in the lungs X-ray before surgery | baseline, pre-surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of : pre-operative vomiting |  | baseline, pre-surgery | 
| pre-operative comfort | pre-operative comfort is evaluated by the EDIN scale | baseline, pre-surgery | 
| pre-operative dehydration |  | baseline, pre-surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypertrophic Pyloric Stenosis, gastric tube, Respiratory Complication
Opioid Induced Bowel Dysfunction in Patients Undergoing Spinal Surgery

Study Overview
=================
Brief Summary
-----------------
In the present study, the primary aim was to evaluate if oxycodone-naloxone combination compared to oxycodone reduced opioid induced constipation in patients with or without chronic opioid treatment undergoing spine surgery.

Official Title
-----------------
Opioid Induced Bowel Dysfunction in Patients Undergoing Spinal Surgery

Conditions
-----------------
Constipation

Intervention / Treatment
-----------------
* Drug: oxycodone-naloxone
* Drug: Oxycodone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI 17 - 35 kg/m2 elective spine surgery informed consent obtained Exclusion Criteria: allergy to the used drugs other contraindication to oxycodone medication no informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Oxycodone-naloxone<br>Oxycodone-naloxone prolonged release tablet twice a day | Drug: oxycodone-naloxone<br> <br> |
| Active Comparator: Oxycodone<br>Oxycodone prolonged release tablet twice a day | Drug: Oxycodone<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| opioid induced constipation | Opioid induced constipation was assessed with bowel function index | from the surgery up to 21 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
constipation, opioid, Oxycodone, Oxycodone-naloxone, spine surgery